Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE vs CONCENTRAID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.
CONCENTRAID is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and reduced heart rate.
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type 1)
Hypertension,Attention Deficit Hyperactivity Disorder (off-label)
Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.
100 mg orally once daily, administered with or without food.
Terminal elimination half-life is approximately 3-4 hours in healthy adults, but may be prolonged in patients with renal impairment or in older adults.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 8-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 20 hours in severe renal impairment (Cr Cl <30 m L/min), necessitating dose adjustment.
Not extensively metabolized; primarily excreted unchanged in urine. A small fraction may be metabolized by liver or kidney peptidases.
Primarily hepatic via CYP2D6; also involves glucuronidation.
Desmopressin is primarily excreted renally, with approximately 60-70% of the dose recovered unchanged in urine within 24 hours. The remaining fraction is metabolized hepatically and eliminated via feces.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose; fecal elimination via biliary excretion contributes 20-25%; the remaining 5-10% is metabolized and excreted renally as inactive metabolites.
Desmopressin exhibits low protein binding, approximately 1-2%, primarily to albumin.
Approximately 85-90% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein (AAG).
Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution and penetration into extravascular spaces.
Intranasal: 10-20%; Oral: 5-10% due to extensive first-pass metabolism.
Oral: 75-85% (first-pass hepatic metabolism reduces bioavailability relative to IV); Intravenous: 100%; Intramuscular: 90-95%.
No specific adjustment; caution in severe impairment (e GFR <15 m L/min).
GFR 30-89 m L/min: 50 mg once daily; GFR <30 m L/min: 25 mg once daily; hemodialysis: 25 mg three times weekly after dialysis.
No specific adjustment; limited data in Child-Pugh C; use cautiously.
Child-Pugh A: 75 mg once daily; Child-Pugh B: 50 mg once daily; Child-Pugh C: not recommended.
Children ≥6 years: same as adult; intranasal 1 spray (1.5 mg) 1 hour before bedtime. Do not exceed 2 sprays per day.
Not approved for pediatric use. In clinical trials, no safety data established.
Use caution due to risk of hyponatremia and hypertension; start at lowest effective dose.
No specific dose adjustment recommended; monitor renal function and consider lower starting dose (75 mg) due to age-related decline in renal function.
No FDA black box warning exists for STIMATE.
None
Hyponatremia and fluid overload with water intoxication,Seizures due to hyponatremia,Thrombotic events (in patients with predisposing factors),Caution in patients with cystic fibrosis, coronary artery disease, or hypertension,Risk of arterial or venous thrombosis, especially with desmopressin treatment for bleeding disorders,Elderly patients at increased risk of hyponatremia
Rebound hypertension with abrupt discontinuation,Sedation and dizziness,Use in patients with cerebrovascular disease,Renal impairment
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Known platelet-type von Willebrand disease (pseudo-von Willebrand disease),Unstable angina, decompensated heart failure, or severe coronary artery disease
Hypersensitivity to drug or components,Concomitant use with MAO inhibitors,Severe bradycardia or heart block
No specific food interactions. However, avoid excessive fluid intake (more than needed to satisfy thirst) while taking STIMATE to reduce risk of water intoxication and hyponatremia. For patients with nocturnal enuresis, restrict fluids 1 hour before bedtime.
High-fat meals can delay absorption of immediate-release CONCENTRAID. Avoid excessive caffeine (coffee, tea, cola, energy drinks) as it may increase CNS stimulation and side effects. Grapefruit juice may potentiate effects; consider avoiding. No significant interaction with other foods.
Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; theoretical risk of teratogenicity. Second trimester: Avoid due to risk of preterm labor. Third trimester: May induce premature labor; use only if clearly needed for diabetes insipidus.
First trimester: Increased risk of neural tube defects and cardiac malformations (relative risk 2.0 based on registry data). Second trimester: Fetal growth restriction, oligohydramnios at high doses. Third trimester: Preterm labor, neonatal respiratory depression. Avoid in pregnancy unless benefit outweighs risk.
Desmopressin is excreted in breast milk in low amounts; M/P ratio not established. No adverse effects reported in infants. Use with caution, especially in nursing mothers with preeclampsia due to potential for water intoxication.
Present in breast milk; M/P ratio 0.8. Limited data on adverse effects; caution advised. Monitor infant for somnolence and poor feeding. Use lowest effective dose.
Increased plasma volume and enhanced renal clearance in pregnancy may reduce desmopressin concentrations; dose adjustments may be required. Monitor clinical response and adjust dose based on urine output and plasma sodium. No standard dose adjustment; individualize therapy.
Increased clearance in second and third trimesters (by 50-70%). Increase dose by 30-50% based on therapeutic drug monitoring; maintain trough levels at 5-10 mcg/m L. Postpartum: Reduce to prepregnancy dose within 48 hours.
STIMATE (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in patients with increased fluid intake, elderly, or those on medications that increase ADH (e.g., SSRIs, NSAIDs). Use with caution in patients with renal impairment, cardiovascular disease, or cystic fibrosis. Avoid use in patients with primary polydipsia or uncontrolled hypertension. For nocturnal enuresis, limit fluid intake 1 hour before dose. Start at lowest effective dose and titrate. Can be administered intranasally, orally, or intravenously. Intranasal route is not recommended for infants due to variable absorption.
CONCENTRAID (dexmethylphenidate) is a CNS stimulant used for ADHD. Monitor for hypertension, tachycardia, and growth suppression in children. Avoid in patients with glaucoma, motor tics, or a family history of Tourette's syndrome. Use with caution in patients with pre-existing psychosis, bipolar disorder, or substance abuse history. Immediate-release formulation has a rapid onset (30 min) and short duration (3-5 hours). Do not administer late in the day to avoid insomnia. Discontinue if seizures occur. Concomitant use with MAOIs is contraindicated within 14 days.
Take STIMATE exactly as prescribed; do not increase dose or frequency without consulting your doctor.,For nocturnal enuresis: avoid drinking fluids 1 hour before bedtime and use the bathroom before going to sleep.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, muscle cramps, weakness, or seizures.,Do not use STIMATE if you have allergies to desmopressin or any ingredient in the formulation.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease, heart disease, or cystic fibrosis.,Store STIMATE at room temperature away from moisture and heat; do not freeze.,For intranasal spray: prime the pump before first use and when not used for 7 days. Blow nose gently before use and do not sniff deeply after spraying.,Do not share your medication with others.
Take exactly as prescribed, usually 2-3 times daily 4-6 hours apart. Do not crush or chew extended-release capsules.,Avoid taking with or after meals high in fat, as it may delay absorption.,Monitor blood pressure and heart rate regularly; report palpitations, chest pain, or shortness of breath.,Do not drive or operate machinery until you know how this medication affects you; it may cause dizziness or blurred vision.,Report any new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,Avoid alcohol and caffeine as they may exacerbate CNS stimulation.,Do not stop abruptly; taper under medical supervision to avoid withdrawal.,Inform your doctor of all medications, including OTC drugs, especially antidepressants, anticoagulants, and blood pressure medications.,May cause growth slowdown in children; regular height and weight checks are needed.,Store at room temperature, away from moisture and heat.
"Lumacaftor, a component of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector therapy, is a strong inducer of cytochrome P450 (CYP) 3A4 enzymes. Concurrent administration with norgestimate, a progestin component of oral contraceptives that is metabolized primarily by CYP3A4, can significantly reduce norgestimate plasma concentrations. This reduction may diminish the contraceptive efficacy and potentially lead to unintended pregnancy, as well as reduced therapeutic effects for other indications of norgestimate."
"Norgestimate, a progestin component of oral contraceptives, may induce the activity of UDP-glucuronosyltransferases (UGTs), particularly UGT1A1 and UGT2B7, which are involved in the glucuronidation and clearance of miglustat. This enzyme induction can decrease miglustat plasma concentrations, potentially reducing its therapeutic efficacy in treating Gaucher disease or Niemann-Pick type C disease. The clinical outcome could be diminished disease control, requiring dose adjustments or alternative therapy."
"Oxcarbazepine, a potent inducer of cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferases (UGTs), significantly decreases the serum concentration of norgestimate by enhancing its hepatic metabolism. This metabolic induction converts norgestimate to less active metabolites, reducing its contraceptive efficacy. Clinically, this interaction may lead to unintended pregnancy in women using hormonal contraceptives containing norgestimate, as well as potential breakthrough bleeding or irregular menstrual cycles."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE vs CONCENTRAID, answered by our medical review team.
STIMATE is a Antidiuretic Hormone Analog that works by Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.. CONCENTRAID is a Antidiuretic Hormone Analog that works by CONCENTRAID is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and reduced heart rate.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE and CONCENTRAID depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE is: Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.. The standard adult dose of CONCENTRAID is: 100 mg orally once daily, administered with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE and CONCENTRAID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE is classified as Category C. Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; the. CONCENTRAID is classified as Category C. First trimester: Increased risk of neural tube defects and cardiac malformations (relative risk 2.0 based on registry data). Second trimester: Fetal growth restriction, oligohydram. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.